Clearside Biomedical Культура компании

Dr. Glenn Noronha, Ph.D., has been the Chief Scientific Officer at Clearside BioMedical, Inc. since August 1, 2016 and served as its Executive Vice President of Research and Development from August 5, 2013 to July 2016. Dr. Noronha has 14 years of experience in the pharmaceutical industry where he served across clinical and nonclinical research and development, product development and other leadership roles. He has led multidisciplinary teams in many fields of medicine including ophthalmology, oncology and immunological and inflammatory diseases. He served as Vice President of Research and Development at Sucampo Pharma Americas, Inc. Dr. Noronha is responsible for the development of the overall product portfolio from research through approval. Dr. Noronha also was named to Sucampo's Global R&D Leadership Team. Dr. Noronha joined Sucampo from JW Theriac, Inc., a pharmaceutical company focused on new drug research and development, which he joined in July 2011 as Chief Scientific Officer, responsible for translational efforts in the oncology therapeutic area. At JW Theriac, he successfully identified and opportunities for research and innovation along with the assessment of risks and technical hurdles. Prior to JW Theriac, Dr. Noronha had leadership roles in Retina Development at Alcon Laboratories, Inc., part of Novartis, from November 2008 to July 2011 as Global Project Head, with global responsibilities for planning and executing all stages of retina development, including working with clinical, regulatory, scientific, non-clinical and technical colleagues for both small molecules and biologics. Previously, from June 2002 to July 2008, Dr. Noronha worked at TargeGen, Inc., acquired by Sanofi-Aventis and held several positions of increasing responsibility, among them Senior Scientist, Group Leader and Director. At TargeGen, he delivered three of the five small molecule candidates into development that were entered into clinical trials; one small molecule candidate resulted in successful phase 2 results. He served at Medtronic MiniMed, Inc. Dr. Noronha is a member of the Association for Research in Vision and Ophthalmology (ARVO) and is named on 21 composition of matter and use patents for drugs in ophthalmology, oncology, immune and inflammatory diseases and in continuous glucose sensing. He is the author of more than 50 peer-reviewed articles and more than 70 scientific presentations at national and international forums. Dr. Noronha earned his Ph.D. in Organometallic Chemistry from Loyola University Chicago and conducted post-doctoral research at the University of California, Irvine in protein structural and bio-organic chemistry.

Mr. Charles A. Deignan, also known as Charlie, has been the Chief Financial Officer at Clearside BioMedical, Inc. since January 2012 and serves as its Secretary. Mr. Deignan served as the President, Chief Financial Officer and Secretary of Atherogenics Inc. since April 1, 2009. Mr. Deignan served as the Vice President of Finance & Administration and Principal Accounting Officer of Atherogenics Inc. since January 1, 2007 and served as its Assistant Secretary since 1999. He served as the Senior Director of Finance & Administration at Atherogenics since January 2002 and as its Director of Finance & Administration from August 1999 to December 2001. Since 1994, Mr. Deignan served several management positions at AAIPharma Inc., including as its Division Controller. He held a number of positions at Schering-Plough Corporation, including as its Finance Manager from 1988 to 1993. Mr. Deignan received a B.S. in Business Administration from Boston University and is a Certified Managerial Accountant.

Mr. Rafael V. Andino has been Vice President of Engineering & Manufacturing at Clearside BioMedical, Inc. since February 2013 and served as its Vice President of Product Development since February 2013. Mr. Andino served as Vice President of Product Development of Clearside BioMedical, Inc. since February 2013. Mr. Andino founded Biofisica, Inc. in 1999 and served as its President. He served as R&D director for CIBA VISION(R) (a Novartis company), a leading global contact lens and lens care company. He has 25 years of experience in the pharmaceutical and medical device industry in both public and private companies serving in product development, research and development and general management roles. He has led multidisciplinary and multinational teams to launch successful products in many fields of medicine including ophthalmology, urology, endourology, gynecology, wound care, cardiovascular and general surgery. He served as the Chief Executive Officer of Biofisica, Inc. He has developed products for the urological, gynecological, general surgical, Ophthalmological and optics markets ??? and has product development knowledge in the orthopedic, vascular and plastic surgery markets. Mr. Andino served as Director of the Advanced Technology Group at CIBA Vision Corporation, part of the Swiss Pharmaceutical firm Novartis Pharma AG. Mr. Andino served as a Senior Project Engineer in the R&D Department of C.R. Bard Inc. and also served in research engineering capacities at the E.I. DuPont de Nemours Company and the IBM Corporation. He served as a Director of Biofisica Inc. Mr. Andino has a Bachelor of Mechanical Engineering with a concentration in Bioengineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering with concentrations in Biomaterials and Biomechanics from the University of Alabama at Birmingham and a Master of Business Administration from the Stetson School of Business and Economics at Mercer University. While a graduate student at the University of Alabama at Birmingham, Mr. Andino extensively studied and documented the relationship between soft tissue wound healing and low level electromagnetic fields.

Glenn Noronha serves as the Chief Scientific Officer; Head of Development of Clearside Biomedical, Inc.. Glenn started at Clearside Biomedical, Inc. in July of 2016. Glenn is currently based in the United States.

Rick McElheny serves as the Vice President Of Business Development of Clearside Biomedical, Inc.. Rick started at Clearside Biomedical, Inc. in November of 2016. Rick is currently based in the Greater Atlanta Area.

Eddy Lee serves as the Vice President CMC of Clearside Biomedical, Inc.. Eddy started at Clearside Biomedical, Inc. in February of 2018. Eddy is currently based in the Greater Atlanta Area.

Rafael Andino serves as the Vice President, Engineering & Manufacturing of Clearside Biomedical, Inc.. Rafael started at Clearside Biomedical, Inc. in February of 2013. Rafael is currently based in the Greater Atlanta Area.

Viral Kansara serves as the Vice President, Discovery of Clearside Biomedical, Inc.. Viral started at Clearside Biomedical, Inc. in September of 2018. Viral is currently based in the Greater Boston Area.